FDA approves Fluzone High-Dose quadrivalent (influenza vaccine) for adults 65 years of age and older

Sanofi

4 November 2019 - Will be available in fall 2020, in time for the 2020-2021 flu season.

The U.S. FDA has approved a supplemental Biologics License Application for Fluzone High-Dose quadrivalent (influenza vaccine) for use in adults 65 years of age and older.

Fluzone High-Dose (Influenza Vaccine) was approved by the FDA in 2009 as a trivalent influenza vaccine, including two influenza A strains and one influenza B strain. Fluzone High-Dose Quadrivalent contains an additional influenza B strain. Fluzone High-Dose Quadrivalent is given to people 65 years of age and older to help prevent influenza disease caused by influenza A and B strains contained in the vaccine.

Read Sanofi press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Outcome , US , Vaccine